New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.05.009 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Julie Malloizel-Delaunay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Medicine Department, University Hospital Center - Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Cancer Lymphedema. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: This phase II trial sought to be the first of its kind to estimate the success rate of endermology in reducing breast cancer-related lymphedema. PATIENTS AND METHODS: ELOCS is a French, monocentric, randomized, open-label phase II trial. Patients were randomized to receive the following over a 5-day treatment period: standard intensive decongestant treatment (IDT) (bandages and manual lymphatic drainage MLD) (group 1); IDT including bandages, MLD, and Cellu M6 (group 2); and IDT including bandages and Cellu M6 (Group 3). The main endpoint was the success rate in each group, (reduction of at least 30% in the excess volume). We estimated that endermology treatment (groups 2 and 3) would be of interest successes occurred in at least 21 out of 31 patients. RESULTS: A total of 93 patients were included (31 patients in each of the 3 groups). The median age was 64.5 years (IQR: [56.4-71.3]). Patients were treated with mastectomy (n = 35), axillary lymphadenectomy (n = 80), radiotherapy (n = 91), and chemotherapy (n = 68). The mean relative reduction in excess volume was 38% in group 1, 33% in group 2, and 34% in group 3. Success rate was 58.1% in group 1 (18/31, P = ,0237), 51.6% (16/31, P = ,5) in group 2, and 64.5% (20/31, P = ,075) in group 3. In the LPG groups (2 and 3), 10/62 (16%) patients found LPG painful and 9/62 (15%) patients considered it to be unpleasant. CONCLUSION: Even though the critical threshold of 21 successes was not met, this study was the first to validate a standardized and reproducible endermology protocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vascular Medicine Department, University Hospital Center - Toulouse, Toulouse, France.
- Department of Oncological Surgery, University Hospital Center - Toulouse, Toulouse University Cancer Institute - Oncopole, Toulouse Cedex 9, France. Electronic address: weyl.a@chu-toulouse.fr.
- Clinical Research Methodological Support Unit (USMR, Unité de Support Méthodologique à la Recherche), Toulouse University Hospital Center - Toulouse, Toulouse Cedex 9.
- Plastic Surgery Department, University Hospital Center - Toulouse, Toulouse, France.
- I2MC INSERM UMR 1048, University Hospital Center - Toulouse -Rangueil, 1 avenue du Professeur Jean Poulhès, 31403 Toulouse, France.
- Department of Oncological Surgery, University Hospital Center - Toulouse, Toulouse University Cancer Institute - Oncopole, Toulouse Cedex 9, France.
Zitieren
APA
Malloizel-Delaunay, J., Weyl, A., Brusq, C., Chaput, B., Garmy-Susini, B., Bongard, V., & Vaysse, C. (2024). New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.05.009
Vancouver
Malloizel-Delaunay J, Weyl A, Brusq C, Chaput B, Garmy-Susini B, Bongard V, et al. New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.05.009
BibTeX
@article{MalloizelDelaunay2024,
author = {Malloizel-Delaunay, Julie and Weyl, Ariane and Brusq, Clara and Chaput, Benoît and Garmy-Susini, Barbara and Bongard, Vanina and Vaysse, Charlotte},
title = {New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.05.009}
}
EUVIMED